Rabeprazole in a one-week eradication therapy of Helicobacter pylori: Comparison of different dosages

• Published in: Journal of gastroenterology and hepatology 2003-07, Vol.18 (7), p.783-786
• Main Authors: MARIO, FRANCESCO DI, DAL BÒ, NADIA, ARAGONA, GIOVANNI, MOUSSA, ALI M, IORI, VERONICA, CAVESTRO, GIULIA M, PILOTTO, ALBERTO, LEANDRO, GIOACCHINO, FRANCESCHI, MARILISA, RUGGE, MASSIMO, FRANZÈ, Angelo
• Format: Article
• Language: English
• Subjects: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents - administration & dosage; Anti-Ulcer Agents - administration & dosage; Antitrichomonal Agents - administration & dosage; Benzimidazoles - administration & dosage; Biological and medical sciences; Breath Tests; Clarithromycin - administration & dosage; different dosage; Digestive system; Drug Therapy, Combination; eradication therapy; Female; Helicobacter Infections - drug therapy; Helicobacter pylori; Humans; Male; Medical sciences; Middle Aged; Omeprazole - analogs & derivatives; Pharmacology. Drug treatments; Rabeprazole; Tinidazole - administration & dosage; Treatment Outcome
• ISSN: 0815-9319; 1440-1746
• DOI: 10.1046/j.1440-1746.2003.03035.x

Aim: Many data regarding omeprazole‐, lanzoprazole‐ and pantoprazole‐based triple therapy for Helicobacter pylori (H. pylori) eradication have been reported, but there is few data present regarding rabeprazole (R). We report the efficacy and tolerability of rabeprazole in different dosages in association with clarithromycin (C)and tinidazole (T) in H. pylori eradication. Design and Methods: Ninety‐four H. pylori‐positive patients with dyspeptic symptoms were enrolled and randomly allocated to eradication therapy in two different one‐week regimens. In regimen A, 47 patients received R 20 mg b.i.d, C 500 mg b.i.d and T 500 mg b.i.d, while in regimen B, 47 patients received R 10 mg b.i.d, C 500 mg b.i.d and T 500 mg b.i.d. Eradication of H. pylori was evaluated by a 13C urea breath test (UBT) two months after the end of the therapy. Results: Four patients (two in each regimen) did not complete treatment. The H. pylori eradication rate was 91.4% in group A compared to 89.3% in group B (P‐value not significant). Minor side‐effects were reported in 4.2% of group A and 6.4% of group B patients. Conclusion: Rabeprazole showed good efficacy and tolerability in one‐week H. pylori therapy at 20 mg b.i.d and 10 mg b.i.d, suggesting the use of the lower dosage. © 2003 Blackwell Publishing Asia Pty Ltd